[go: up one dir, main page]

MX2018004794A - Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxym ethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinol in-2(1h)-yl]ethanone for the treatment of parkinson's disease. - Google Patents

Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxym ethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinol in-2(1h)-yl]ethanone for the treatment of parkinson's disease.

Info

Publication number
MX2018004794A
MX2018004794A MX2018004794A MX2018004794A MX2018004794A MX 2018004794 A MX2018004794 A MX 2018004794A MX 2018004794 A MX2018004794 A MX 2018004794A MX 2018004794 A MX2018004794 A MX 2018004794A MX 2018004794 A MX2018004794 A MX 2018004794A
Authority
MX
Mexico
Prior art keywords
ethanone
methylbutyl
dichlorophenyl
methyl
crystalline form
Prior art date
Application number
MX2018004794A
Other languages
Spanish (es)
Inventor
Alan Stephenson Gregory
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2018004794A publication Critical patent/MX2018004794A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a crystalline form of 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydrox y-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl ]ethanone, and pharmaceutical compositions thereof. The invention further provides methods of using a crystalline form of 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydrox y-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl ]ethanone to treat cognitive impairment associated with Parkinson's disease or schizophrenia.
MX2018004794A 2015-10-23 2016-10-18 Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxym ethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinol in-2(1h)-yl]ethanone for the treatment of parkinson's disease. MX2018004794A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562245391P 2015-10-23 2015-10-23
PCT/US2016/057447 WO2017070068A1 (en) 2015-10-23 2016-10-18 Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
MX2018004794A true MX2018004794A (en) 2018-06-19

Family

ID=57233858

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004794A MX2018004794A (en) 2015-10-23 2016-10-18 Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxym ethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinol in-2(1h)-yl]ethanone for the treatment of parkinson's disease.

Country Status (13)

Country Link
CN (1) CN108137506A (en)
AR (1) AR106332A1 (en)
AU (1) AU2016341115A1 (en)
CA (1) CA2999332A1 (en)
DO (1) DOP2018000103A (en)
EA (1) EA201890525A1 (en)
EC (1) ECSP18030976A (en)
IL (1) IL257872A (en)
MX (1) MX2018004794A (en)
PE (1) PE20181296A1 (en)
PH (1) PH12018500859A1 (en)
TW (1) TW201725199A (en)
WO (1) WO2017070068A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI725408B (en) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 Dopamine d1 receptor positive allosteric modulators
MD3897578T2 (en) 2018-12-18 2025-04-30 Lilly Co Eli Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
TWI825323B (en) * 2019-06-18 2023-12-11 美商美國禮來大藥廠 Processes and intermediates for the preparation of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone
AU2022234744B2 (en) * 2021-03-08 2025-06-26 Eli Lilly And Company Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
AU2022234226B2 (en) * 2021-03-09 2025-08-14 Eli Lilly And Company Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression
CN113264926A (en) * 2021-05-31 2021-08-17 东北林业大学 Co-crystal of vitexin and reserpine and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
EP2125741A1 (en) * 2007-03-01 2009-12-02 Janssen Pharmaceutica, N.V. Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
US20120252853A1 (en) * 2011-04-01 2012-10-04 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
JO3316B1 (en) * 2013-05-30 2019-03-13 Lilly Co Eli 3,4-dihydroisoquinolin-2(1h)-yl compounds

Also Published As

Publication number Publication date
PE20181296A1 (en) 2018-08-07
CA2999332A1 (en) 2017-04-27
AU2016341115A1 (en) 2018-04-12
CN108137506A (en) 2018-06-08
DOP2018000103A (en) 2018-10-31
ECSP18030976A (en) 2018-05-31
AR106332A1 (en) 2018-01-03
TW201725199A (en) 2017-07-16
PH12018500859A1 (en) 2018-10-29
EA201890525A1 (en) 2018-09-28
WO2017070068A1 (en) 2017-04-27
IL257872A (en) 2018-06-03

Similar Documents

Publication Publication Date Title
PH12018500859A1 (en) Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease
IL285782A (en) Compounds, compositions, and methods for the treatment of disease
MX2021000071A (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease.
PH12018500960A1 (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
PE20152032A1 (en) 3,4-DIHYDROISOQUINOLIN-2 (1H) -IL COMPOUNDS
IL278178A (en) Use of pilocarpine hydrochloride for the treatment of ocular conditions
EP4582144A3 (en) Agents, uses and methods for the treatment of synucleinopathy
MX375639B (en) SUBSTITUTED HETEROCYCHYL DERIVATIVES AS CDK INHIBITORS
WO2016037157A3 (en) Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
WO2015001504A3 (en) Antibody formulations and methods
HK1206726A1 (en) Imidazotriazinone compounds
IL286340A (en) Local formulations for the treatment of peripheral nervous system diseases
MX2017009417A (en) Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof.
WO2018067520A3 (en) Therapeutic agents and methods:
NZ746468A (en) Methods of treating ocular conditions
MX381224B (en) POWERFUL GAMMA-SECRETASE MODULATORS.
EA201691567A1 (en) METHODS OF TREATING PULMONARY INJURIES TO THE BRAIN
MX2018001592A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISORDERS.
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
TN2016000447A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands.
IL288521A (en) Processes and intermediates for the preparation of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethenone
MA39450A1 (en) Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
WO2017103892A3 (en) Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease
WO2015162552A3 (en) Composition for topic use
MX2019002629A (en) Crystalline forms of therapeutic compounds and uses thereof.